TTrialPathMatch Me to Trials
← Back to trials
RecruitingAlzheimer Disease

Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

Eligible age

45–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a research study to evaluate the safety of an investigational autologous cell product obtained from participant's own adipose tissue as a possible treatment for Alzheimer disease.

Sponsor: Regeneration Biomedical, Inc.

You may qualify if…

  • ≥45 and ≤80 years of age
  • Mild to moderate AD diagnosis
  • Adequate cognitive function
  • Non-remarkable clinical laboratory
  • Ability to voluntarily provide written informed consent
  • No tumors or other disease responsible for dementia
  • Well-controlled comorbidities, on stable medications for 3 months
  • The participant is otherwise in good general health

You may not qualify if…

  • Taking other medications for AD, except that donepezil memantine, AChEIs including patches, Vitamin E, fish oil, and/or gingko biloba are allowed if doses have been stable for at least 3 months prior to the Screening visit
  • Stem cell implantation of any type within 3 months
  • Existing ventriculoperitoneal shunts
  • Neurological disorders except AD
  • Psychiatric disorders including schizophrenia, bipolar/unipolar depressive disorder, delirium
  • Drug or alcohol abuse or dependence within the past 5 years
  • Participants with a history of cancer in the past 5 years
  • No caregiver available to meet the inclusion criteria for caregivers

Where it's recruiting

California

Newport Beach

Source: ClinicalTrials.gov · NCT05667649 · last updated 2025-04-04

Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Dir · TrialPath